Breaking News Instant updates and real-time market news.

AGN

Allergan

$227.94

3.95 (1.76%)

, TBRA

Tobira Therapeutics

$40.28

0.18 (0.45%)

08:01
10/19/16
10/19
08:01
10/19/16
08:01

Allergan, Tobira Therapeutics announce early termination of HSR waiting period

Allergan (AGN) and Tobira Therapeutics (TBRA) announced that the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, with respect to Allergan's pending acquisition of Tobira. The early termination of the HSR waiting period satisfies one of the conditions to the closing of the pending acquisition, which remains subject to other customary closing conditions. Both companies expect the transaction to be completed by the end of 2016.

AGN

Allergan

$227.94

3.95 (1.76%)

TBRA

Tobira Therapeutics

$40.28

0.18 (0.45%)

  • 26

    Oct

  • 02

    Nov

  • 06

    Nov

AGN Allergan
$227.94

3.95 (1.76%)

09/21/16
GABE
09/21/16
NO CHANGE
GABE
Buy
Gabelli questions if Allergan could target Gilead next
Gabelli analyst Kevin Kedra said that "like most" he was surprised at the price paid and the strategic fit of Allergan's (AGN) deal to buy Tobira Therapeutics (TBRA), but wonders if Allergan CEO Brent Saunders is "playing chess while the market is playing checkers" and could be preparing a bid for Gilead (GILD). After Allergan's "very loud statement about its commitment to NASH and liver disease," a deal for Gilead, the leading company in liver disease and "one of the cheapest companies in pharma/biotech," would appear to make more sense, Kedra tells investors, adding that an acquisition of Gilead at a price of $115 per share would be "highly accretive" for Allergan. The analyst keeps a Buy rating on Allergan shares.
09/22/16
BERN
09/22/16
NO CHANGE
BERN
Allergan acquisitions positive, says Bernstein
After Allergan bought two companies with NASH drugs and the stock fell, Bernstein analyst Aaron Gal says the acquisitions were viewed as expensive. Gal says "it makes almost no difference" if the deals were expensive, as the important issue is whether the products succeed. He believes that the market would never penalize Roche or Celgene for similar deals, and he thinks this indicates that Allergan is "misvalued." He says that Allergan is his "high conviction buy" stock and keeps a $335 price target on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
10/14/16
LEER
10/14/16
NO CHANGE
Target $294
LEER
Outperform
Leerink positive on Allergan ahead of Restasis patent decision
Leerink analyst Jason Gerberry is positive on Allergan's franchise outlook as he believes the company will either maintain a double-digit top-line" growth pharma" trajectory or alternatively institute a dividend, and will prevail in the ongoing Restasis patent challenge. Gerberry likes Allergan's underlying growth trends of the gastro and derm franchises and pipeline optionality, and reiterates an Outperform rating and $294 price target on the shares.
TBRA Tobira Therapeutics
$40.28

0.18 (0.45%)

09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.
09/21/16
BARD
09/21/16
NO CHANGE
Target $332
BARD
Outperform
Intercept undervalued based on Allergan's upfront payment for Tobira, says Baird
Baird analyst Brian Skorney is positive on the yesterday's merger activity in the NASH space, specifically Allergan's (AGN) offer to buy Tobira Therapeutics (TBRA). Based on the upfront payment to Tobira from Allergan, Skorney said he can't help but question whether Intercept (ICPT) shares are undervalued. Skorney reiterated his Outperform rating on Intercept shares and keeps a $332 price target on the stock.
09/21/16
CANT
09/21/16
DOWNGRADE
CANT
Hold
Tobira Therapeutics downgraded to Hold from Buy at Cantor
Cantor analyst Elemer Piros downgraded Tobira (TBRA) after the company agreed to be acquired by Allergan (AGN). Target to $42 from $19.

TODAY'S FREE FLY STORIES

MSTX

Mast Therapeutics

$0.14

0.003 (2.22%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Mast Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MTSI

MACOM

$50.32

-3.52 (-6.54%)

, SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$50.32

-3.52 (-6.54%)

SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

NXST

Nexstar

$69.90

1 (1.45%)

TRCO

Tribune Media

$36.72

0.17 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

CLLS

Cellectis

$23.83

0.26 (1.10%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Cellectis management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 06

    Jun

RDHL

RedHill Biopharma

$10.29

0.0199 (0.19%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
RedHill Biopharma to host research and development day »

Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

RXDX

Ignyta

$9.20

0.25 (2.79%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Ignyta holds a conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

BGG

Briggs & Stratton

$25.14

0.09 (0.36%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 10

    May

GTN

Gray Television

$15.05

0.4 (2.73%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Gray Television management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 04

    May

SGM

Stonegate Mortgage

$7.96

-0.0059 (-0.07%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Stonegate Mortgage to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

CMRX

Chimerix

$6.09

-0.01 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Chimerix to hold an investor update webcast »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Pending Home Sales Index to be reported at 10:00 »

March Pending Home Sales…

RGLS

Regulus

$1.55

0.1 (6.90%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Regulus management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Berenberg to hold a conference »

U.K. Corporate Conference…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
The Food & Drug Law Institute to hold a conference »

Introduction to U.S. Drug…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/21 EIA Natural…

MEOH

Methanex

$46.10

0.15 (0.33%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Methanex Corporation to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

WWD

Woodward

$68.05

-0.11 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Woodward management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 09

    May

  • 11

    May

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/22 Jobless…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/23 Bloomberg…

LGF

Use LGF.A, LGF.B

, AMCX

AMC Networks

$60.25

0.65 (1.09%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
FBN Securities media/cable analyst holds an analyst/industry conference call »

Media. Cable &…

LGF

Use LGF.A, LGF.B

AMCX

AMC Networks

$60.25

0.65 (1.09%)

DISCA

Discovery

$29.39

0.1 (0.34%)

CBS

CBS

$66.91

0.5 (0.75%)

NFLX

Netflix

$150.17

-1.99 (-1.31%)

AMZN

Amazon.com

$909.29

1.67 (0.18%)

VIA.B

Symbol now VIAB

NLSN

Nielsen

$39.41

-0.57 (-1.43%)

SNI

Scripps Networks

$76.49

0.53 (0.70%)

TWX

Time Warner

$100.20

0.16 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 05

    Jun

  • 15

    Jun

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/26 Fed Balance…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/17 Money Supply…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.